[1] Costachescu D, Ionita I, Borsi EC, et al.Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma[J]. Exp Ther Med, 2021, 22(2): 827-830. [2] 严志民,刘彦权,黄走方,等. T细胞亚群与细胞因子水平变化在多发性骨髓瘤患者临床诊疗及预后评估中的价值[J]. 中国实验血液学杂志,2022,30(6):1791-1796. [3] Delgado J, Zienowicz M, van Hennik PB, et al. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma[J]. Oncologist, 2021, 26(11): 983-987. [4] Rahman M, Keegan A, Mateus J, et al.Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: :a retrospective cohort study[J]. Leuk Lymphoma, 2023, 64(2): 388-397. [5] 薛冬玲,张瑞春,张颖. 63例年龄>60岁多发性骨髓瘤周围神经病变患者自我感受负担量表评分的影响因素及干预策略[J]. 吉林医学,2022,43(10):2658-2660. [6] Wang L, Wang JH, Liu WJ, et al.High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma[J]. Ann Hematol, 2017, 96(12): 2079-2088. [7] Huo YJ, Xu PP, Wang L, et al.Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma[J]. Biomark Res, 2022, 10(1): 51-53. [8] 中国多发性骨髓瘤工作组. 中国多发性骨髓瘤诊治指南[J]. 中华内科杂志,2008,47(10):4. [9] Boyle EM, Rosenthal A, Wang Y, et al.High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse[J]. Br J Haematol, 2021, 195(2): 283-286. [10] 邝丽芬,房佰俊,陈文明,等. 含塞利尼索方案治疗复发难治多发性骨髓瘤的疗效与安全性分析:一项中国多中心真实世界研究[J]. 临床血液学杂志,2022,35(9):626-632. [11] 林萍,林晓容,刘巧灵,等. sIL-2R在多发性骨髓瘤患者中的表达及其临床意义[J]. 中国实验血液学杂志,2022,30(6):1797-1802. [12] Uryu H, Nakamura T, Nakashima D, et al.Miliary tuberculosis-associated hemophagocytic lymphohistiocytosis with a high level of soluble interleukin-2 receptor successfully treated with concomitant recombinant thrombomodulin: A case report[J]. J Infect Chemother, 2023, 29(3): 361-366. [13] Wang L, Wang JH, Liu WJ, et al.High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma[J]. Ann Hematol, 2017, 96(12): 2079-2088. |